Dr. Khandros will remain on the board of directors of Nutcracker Therapeutics, and Cynthia Collins will serve as executive ...

Codexis (CDXS) announced the appointment of Cynthia Collins to the Company’s Board of Directors. She currently serves as Executive Chair and ...

Collins, 66, currently serves as Executive Chair and Interim Chief Executive Officer of Nutcracker Therapeutics, Inc. since February 2025. Her previous roles include CEO positions at Editas ...

Collins, 66, currently serves as Executive Chair and Interim Chief Executive Officer of Nutcracker Therapeutics, Inc. since February 2025. Her previous roles include CEO positions at Editas Medicine ...

Board of directors member, Cynthia Collins, will serve as executive chair Dr. Khandros will remain on the board of Nutcracker Therapeutics EMERYVILLE, Calif.--(BUSINESS WIRE)--Nutcracker Therapeutics, ...

EMERYVILLE, CA, USA I March 26, 2025 I Nutcracker Therapeutics, Inc., a contract, research, development and manufacturing organization (CRDMO) with a next generation RNA precision manufacturing ...

Nutcracker Therapeutics, Inc., a contract, research, development and manufacturing organization (CRDMO) with a next ?generation RNA precision manufacturing platform, announced today that Chief ...

CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opportunities, marking the latest shakeup to the ...